Research programme: anticancer peptide aptamers - Aptanomics SA
Alternative Names: AP 1; AP 2; AP 3; AptamersLatest Information Update: 04 Nov 2017
At a glance
- Originator Aptanomics
- Class Peptide aptamers; Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France
- 06 Nov 2006 This programme is still in active development
- 25 Mar 2004 Preclinical trials in Cancer in France (unspecified route)